Lv11
20 积分 2022-12-02 加入
Inebilizumab for Treatment of IgG4-Related Disease
6小时前
已完结
Cancer immunotherapy by γδ T cells
1个月前
已完结
Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy
1个月前
已完结
BCMA-Targeted T-Cell–Engager Therapy for Autoimmune Disease
2个月前
已完结
Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 Radionuclides
7个月前
已完结
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study
8个月前
已完结
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single and MultipleAscending Dose Study of AMG 133 in Subjects with Obesity
8个月前
已完结
Biopharma dealmaking in 2023
8个月前
已完结
Preclinical pharmacokinetics of a novel anti-c-Met antibody–drug conjugate, SHR-A1403, in rodents and non-human primates
9个月前
已完结
A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1)
11个月前
已关闭
皖公网安备34019202002308
